Literature DB >> 2655238

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

P T Männistö, S Kaakkola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2655238     DOI： 10.1016/0165-6147(89)90075-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  20 in total

1.  PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.

Authors:  T Lotta; J Taskinen; R Bäckström; E Nissinen
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

2.  The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Authors:  E Nissinen; H Nissinen; H Larjonmaa; A Väänänen; T Helkamaa; I Reenilä; P Rauhala
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

3.  Parkinson's disease.

Authors:  D Mukherjee; I R Hastie
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

4.  The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit.

Authors:  B Friedgen; T Halbrügge; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

Review 5.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

7.  The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.

Authors:  S Sundberg; M Scheinin; P Ojala-Karlsson; J Akkila; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.

Authors:  M A Vieira-Coelho; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.

Authors:  P T Männistö; P Tuomainen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

10.  Clinical pharmacology of the new COMT inhibitor CGP 28,014.

Authors:  P R Bieck; K H Antonin; G Farger; E B Nilsson; E K Schmidt; P Dostert; M Strolin Benedetti; P C Waldmeier
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.